Idenix Pharmaceuticals, Inc. is engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Building on its expertise in nucleoside chemistry and other small molecule chemistry and biology, the company is well positioned to become a leader in antiviral pharmaceuticals. Idenix's current focus is on the treatment of hepatitis C virus (HCV) infections. The company has previously discovered and developed antivirals for the treatment of hepatitis B virus (HBV) and HIV/AIDS.
Idenix discovered, co-developed and co-launched telbivudine (Tyzeka®/Sebivo®) for the treatment of HBV, for which Novartis Pharma AG now has worldwide commercialization rights.
Idenix has focused its efforts towards HCV due to the global unmet medical need for this viral disease. It is estimated that more than 170 million people worldwide are chronically infected with HCV.
Idenix is headquartered in Cambridge, Massachusetts (MA). Its clinical development operations and drug discovery operations are conducted in Cambridge, MA and the company’s European laboratories in Montpellier, France.